Position in ROIV
as of Mar 31, 2026
· filed Apr 2, 2026
Position Value
$5,540
+$1,200 QoQ
Shares Held
200
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Aspect Partners, LLC holds $49,014 across 13 Biotechnology names. ROIV ranks #3 (11.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22 | $16,997 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
21 | $9,377 | |
| 3 | ROIV |
Roivant Sciences Ltd.
This page
|
200 | $5,540 | |
| 4 | DYN |
Dyne Therapeutics, Inc.
|
225 | $4,079 | |
| 5 | TLX |
Telix Pharmaceuticals Ltd
|
380 | $3,636 | |
| 6 | LEGN |
Legend Biotech Corp
|
151 | $2,731 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
43 | $2,429 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
20 | $1,501 |
All Filings in ROIV
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,540 | 200 | Shares | Sole | 2026-04-02 | |
| 2025-12-31 | $4,340 | 200 | Shares | Sole | 2026-01-23 | |
| No filing history on record for this holder in this stock. | ||||||